<AI1>
Informal
pre-meeting (09.15 - 09.30)
</AI1>
<AI2>
1
Introductions, apologies, substitutions
and declarations of interest
</AI2>
<AI3>
2
Use of antipsychotic medication in care
homes - evidence session 4 - Public Health Wales NHS
Trust
(09.30 -
10.15)
(Pages 1 - 26)
Michaela Morris, Mental Health Service
Improvement Manager, Public Health Wales.
Rhiannon Davies
</AI3>
<AI4>
Break (10.15
- 10.20)
</AI4>
<AI5>
3
Use of antipsychotic medication in care
homes - evidence session 5 - Royal College of Psychiatrists and
Royal College of General Practitioners
(10.20 -
11.05)
(Pages 27 - 33)
Dr Victor Aziz, Royal College of
Psychiatrists
Dr Jane Fenton-May, Royal College of General
Practitioners
</AI5>
<AI6>
Break (11.05
- 11.15)
</AI6>
<AI7>
4
Use of antipsychotic medication in care
homes - evidence session 6 - Royal College of Nursing
(11.15 -
11.45)
(Pages 34 - 35)
Alison Davies, Associate Director Professional
Practice, Royal College of Nursing Wales
Helen Bennett, Mental Health Nurse and Mental
Health Consultant, Royal College of Nursing Wales
</AI7>
<AI8>
Break (11.45
- 11.50)
</AI8>
<AI9>
5
Use of antipsychotic medication in care
homes - evidence session 7 - Royal Pharmaceutical Society and
Community Pharmacy Wales
(11.50 -
12.35)
(Pages 36 - 45)
Mair Davies, Director, Royal Pharmaceutical
Society Wales
Wendy Davies, Mental Health Clinical Board
Pharmacist, Royal Pharmaceutical Society Wales
Steve Simmonds, Community Pharmacy Wales
Sam Fisher, Community Pharmacy Wales
</AI9>
<AI10>
Lunch (12.35
- 13.15)
</AI10>
<AI11>
6
Use of antipsychotic medication in care
homes - evidence session 8 - British Psychological
Society
(13.15 -
13.45)
(Pages 46 - 86)
Dr Ian James, British Psychological
Society
Dr Carolien Lamers, British Psychological
Society
</AI11>
<AI12>
7
Paper(s) to note
</AI12>
<AI13>
7.1 Inquiry into the use of antipsychotic medication in
care homes - note of session on 21 September 2017
(Pages 87 - 88)
</AI13>
<AI14>
8
Motion under Standing Order 17.42 to
resolve to exclude the public from the remainder of the
meeting
</AI14>
<AI15>
9
Use of antipsychotic medication in care
homes - consideration of evidence
(13.45 -
14.00)
</AI15>
<AI16>
10 Inquiry into loneliness and isolation - consideration
of draft report
(14.00 -
15.00)
(Pages 89 - 126)
</AI16>
<TRAILER_SECTION>
</TRAILER_SECTION>
<LAYOUT_SECTION>
1.FIELD_TITLE
FIELD_FOOTNOTE F_PR
FIELD_SUMMARY
</LAYOUT_SECTION>
<TITLE_ONLY_LAYOUT_SECTION>
2.FIELD_TITLE
FIELD_FOOTNOTE F_PR
</TITLE_ONLY_LAYOUT_SECTION>
<HEADING_LAYOUT_SECTION>
FIELD_TITLE
FIELD_FOOTNOTE
</HEADING_LAYOUT_SECTION>
<TITLED_COMMENT_LAYOUT_SECTION>
FIELD_TITLE
FIELD_FOOTNOTE
FIELD_SUMMARY
</TITLED_COMMENT_LAYOUT_SECTION>
<COMMENT_LAYOUT_SECTION>
FIELD_SUMMARY
</COMMENT_LAYOUT_SECTION>
<SUBNUMBER_LAYOUT_SECTION>
2.1.FIELD_TITLE
FIELD_FOOTNOTE F_PR
FIELD_SUMMARY
</SUBNUMBER_LAYOUT_SECTION>
<TITLE_ONLY_SUBNUMBER_LAYOUT_SECTION>
2.2.FIELD_TITLE
FIELD_FOOTNOTE F_PR
</TITLE_ONLY_SUBNUMBER_LAYOUT_SECTION>